Fortrea Holdings Inc FTRE

$21.29 -1.84 (-7.97%)

Valuation

Market cap
2,024,679,000
Revenue TTM
$2,723,400,000
Net income TTM
$-986,200,000
P/E (trailing)
30.44
P/E (forward)
27.02
Profit margin
-36.21%
Debt to equity
2.01

Trading

Volume
2,873,500
Avg volume
1,687,346
Day's range
$20.70 – $23.51
Shares out
95,100,000
Stochastic %K
11%
Beta
1.93
Analysts
Moderate Buy
Price target
$23.82

Price

Company profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and...

Show more

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Phone
877 495 0816
Website
https://www.fortrea.com
Address
8 Moore Drive, Durham, United States

Latest news

Stocktwits

shoc24 Oct 29, 4:13 PM
$FTRE reported earnings before the open: adjusted EPS of $0.28 vs. $0.22 estimated, a beat of 28.9%. I used Stock Meadow to review the results.
0 replies
EarningsInsider Oct 29, 1:17 PM
https://www.marketbeat.com/earnings/reports/2026-10-29-fortrea-holdings-inc-stock/ $FTRE Fortrea Earnings Transcript
0 replies
StocktwitsEarnings Oct 29, 10:43 AM
$FTRE Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.28 up 133.33% YoY • Reported revenue of $691.5M down -1.40% YoY • Fortrea raised midpoints and narrowed ranges for full-year 2026 guidance, expecting revenue of $2.67B to $2.69B and adjusted EBITDA of $210M to $218M.
0 replies
filecrux Oct 29, 10:41 AM
$FTRE Does Fortrea's $558M backlog cut outweigh the higher midpoints on its 2026 revenue and EBITDA guidance? 🏢 Fortrea, a contract research organization that runs clinical trials for drugmakers, reported third-quarter 2026 results and cut its backlog by $558M after a contract review, leaving $7,316M at September 30 🧾 The cut is about 7% of the backlog before the change, about a fifth of this year's revenue guidance midpoint, and about 23% of the company's roughly $2.46B market value at $25.88 a share at 16:00 ET on October 28, 2026 ✅ The company says the cut does not touch 2026 guidance or near-term revenue estimates, and its 1.12x book-to-bill means new orders still outran revenue in the quarter 📅 Next: Earnings call at 8:00 am ET on October 29, 2026; watch which contracts and trials drove the cut Source: GlobeNewswire releases, Oct 29 and Jul 29, 2026
0 replies
shoc24 Oct 28, 10:42 PM
$FTRE is estimated to report earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: FTRE has beaten EPS estimates in 4 of its last 8 reports.
0 replies
STRelativeStrength Oct 28, 3:20 PM
$FTRE undiscovered breakout with 222 watchers
0 replies
Rayvio_News_Filter Oct 20, 6:43 PM
$FTRE 🤝 Fortrea Holdings Inc completed its all-cash acquisition of Worldwide Clinical Trials' Early Phase Services division for approximately $45 million, adding GLP bioanalytical labs and a 200-bed clinical pharmacology unit to expand early clinical development capacity. Selected from hundreds of headlines
0 replies
STRelativeStrength Oct 20, 6:20 PM
$FTRE undiscovered breakout with 218 watchers
0 replies